Allergy Therapeutics plc (FRA:HHU)

Market Cap	733.55M
Revenue (ttm)	67.30M
Net Income (ttm)	-43.11M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,092
Average Volume	14,139
Open	0.1020
Previous Close	0.1030
Day's Range	0.1020 - 0.1160
52-Week Range	0.0510 - 0.1160
Beta	n/a
RSI	67.66
Earnings Date	Nov 20, 2025

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to ad...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 612
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HHU

Financial Performance

In 2024, Allergy Therapeutics's revenue was 55.20 million, a decrease of -7.36% compared to the previous year's 59.59 million. Losses were -40.22 million, -6.63% less than in 2023.

Financial numbers in GBP